| 摘要: |
| ［摘要］ 目的 初步探讨重组人p53腺病毒（rAd-p53）鼻咽部瘤内注射前后的鼻咽癌原发灶中胸苷酸合成酶（TS）、谷胱甘肽S-转移酶π（GST-π）和拓扑异构酶Ⅱ（TopoⅡ）的表达变化及其临床意义。方法 采用免疫组化法检测80例晚期鼻咽癌患者治疗前后肿瘤组织中TS、GST-π和TopoⅡ的表达情况。结果 常规放化疗组在治疗后其TS、GST-π和TopoⅡ的表达明显升高（P分别为0.01、0.01、0.00），基因治疗组和单纯放疗组其治疗后TS、GST-π和TopoⅡ的表达未见明显改变（P>0.05）。三组间的复发率和转移率差异无统计学意义(P=0.95)。疗前GST-π阴性患者其复发率和转移率明显低于阳性患者（8.93% vs 54.17%，P=0.00）。结论 GST- π蛋白的异常表达与晚期鼻咽癌治疗后复发转移有关。基因治疗晚期鼻咽癌可能通过抑制TS、GST-π、TopoⅡ蛋白表达进而逆转鼻咽癌化疗耐药。 |
| 关键词: p53基因治疗 化疗耐药 TS GST-π TopoⅡ |
| DOI：10.3969/j.issn.1674-3806.2012.12.09 |
| 分类号:R 739.63 |
| 基金项目:广西卫生厅重点科研课题（编号：重200721） |
|
| The expression of TS, GST-π, TopoⅡ in advanced nasopharyngeal carcinoma patients treated with gene therapy and its influence on prognosis |
|
ZHANG Zheng, WENG Jing-jin, WEI Hai-ming, et al.
|
|
Department of Otolaryngology Head and Neck Oncology, the People′s Hospital Guangxi Zhuang Autonomous Region, Nanning 530021,China
|
| Abstract: |
| ［Abstract］ Objective To investigate the expression of thymidylate synthase (TS), glutathione S-transferase enzyme π(GST-π) and topoisomerase Ⅱ (Topo Ⅱ) protein before and after the recombinant human p53 adenovirus (rAd-p53) intratumoral injection and its significance.Methods Eighty patients with advanced nasopharyngeal carcinoma were randomly divided into 3 groups：the gene therapy group (30 cases): rAd-p53 intratumoral injection and concurrent chemo-radiotherapy, the conventional chemoradiotherapy group (30 cases) and the radiotherapy group (20 cases). Clinical data and the nasopharyngeal tumor tissues which were intratumoral injection with rAd-p53 were collected. The two-step immunohistochemical was done to detect the TS, GST- π and TopoⅡ protein expression in the primary tumor tissue of nasopharyngeal carcinoma.Results The expression TS, GST-π and Topo Ⅱ in conventional chemoradiotherapy group was significantly higher than that before treatment (P values were 0.01,0.01,0.00). In gene treatment group, the expression TS, GST-π and Topo Ⅱdid not change significantly (P>0.05).There were no significant difference in the expression of TS, GST-π and Topo Ⅱbefore and after radiotherapy alone(P>0.05). Among the three groups, the recurrence rate and metastasis rate were not significantly different (P = 0.95). The recurrence rate in GST-π negative patients was significantly lower than that in positive patients (8.93% vs. 54.17%, P = 0.00).Conclusion GST-π protein expression is positively correlated with recurrence and metastasis in patients with advanced nasopharyngeal carcinoma after treatment.The rAd-p53 intratumoral injection can reverse chemo-resistance of nasopharyngeal carcinoma by inhibition of GST-π, Topo Ⅱ protein, which might be its mechanism of NPC treatment. |
| Key words: p53 gene therapy Resistance to chemotherapy TS GST-π Topo Ⅱ |
